Kaplan-Meier analysis of bleeding risk according to baseline characteristics and remission status. (A) Frequency of patients with bleeding event after day 1 of study (102 patients; red line, total bleeds; blue line, treated bleeds only) and after the day of first PR (81 patients; green line, total bleeds). All events include recurrent and nonrecurrent bleeding events. (B) Frequency of patients with bleeding event after day 1 according to baseline FVIII activity (102 patients). (C) Frequency of patients with bleeding event after day 1 according to baseline FVIII inhibitor (102 patients). In all panels, patients no longer at risk (because of death or end of follow-up) were censored.